|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
|---|---|
| Information provided by: | National Heart, Lung, and Blood Institute (NHLBI) |
| ClinicalTrials.gov Identifier: | NCT00149474 |
Purpose
Evaluate the incremental effectiveness of peak flow monitoring ove symptom monitoring as a management tool to enhance asthma control in adults >= 50 years with moderate-severe asthma.
| Condition | Intervention |
|---|---|
|
Asthma |
Behavioral: Peak Flow Monitoring |
| Study Type: | Interventional |
| Study Design: | Randomized |
| Study Start Date: | August 1994 |
| Estimated Study Completion Date: | July 1999 |
BACKGROUND:
We propose a five-year Demonstration and Education project to assess the incremental value of peak flow monitoring (PFM) over symptom monitoring (SM) as a management tool for asthma control in adults greater than or equal to 50 years with moderate-severe asthma. We will develop three parallel asthma education programs for older adults using as our base an existing asthma education program (AIR/Kaiser Adult Education Program) of demonstrated efficacy for adults ,50 years of age.
DESIGN NARRATIVE:
Primary outcome Frequency and cost of health care utilization for asthma, and asthma-specific quality of life
Key secondary outcomes Prebronchodilator FEV1; diurnal variability in PEF
Eligibility| Ages Eligible for Study: | 50 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusions: Doctor-diagnosed asthma; >=50 years; using asthma medications; >12% increase in FEV1 after two puffs of inhaled beta-agonist; willing to participate in asthma meducation program and two-year follow up; likely to stay in Portland area; KPNW member for two years.
Exclusions: Unable to read, speak or understand English; no telephone; failure to keep two pre-randomization appointments; inability to reproducible FEV 1 maneuver; participation in pilot phase of study; concurrent participation in any other medical research study.
Contacts and Locations More Information
| Study ID Numbers: | 260 |
| Study First Received: | September 6, 2005 |
| Last Updated: | September 6, 2005 |
| ClinicalTrials.gov Identifier: | NCT00149474 |
| Health Authority: | United States: Federal Government |
|
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Respiratory Hypersensitivity |
|
Immune System Diseases Bronchial Diseases |
